Skip to content
Menu

Aurinia Pharmaceuticals Inc. AUPH

Full chart Compare
Set alert

Price alert · AUPH

All alert types
14.76 USD -0.13 (-0.87%)

As ofNov 20, 2026, 2:56 PM EST

14.63 Day range 14.97
13.52 52-week range 19.25
YTD
-7.46%
1 year
-2.51%

5D -1.21 (-7.52%)

1515.5016FriMonTueWedThu14.89
Market cap
1.98B
Revenue (ttm)
321.74M
Profit margin
97.68%
EPS (ttm)
2.28
Shares out
134.00M
P/E ratio
6.47
Forward P/E
12.84
YTD return
-7.46%
1-year return
-2.51%
50-day average
16.43
Volume
819.00K
Avg volume
857.29K
Open
14.72
Previous close
14.89
Day's range
14.63 – 14.97
52-week range
13.52 – 19.25
Beta
1.34
Analysts
Buy
Price target
18.50 (+25.3%)
Earnings date
Feb 25, 2027

Key statistics

200-day average
15.74
Enterprise value
1.60B
Price / sales
6.20
Price / book
3.03
Revenue growth
13.90%
Free cash flow
140.48M
Total cash
486.53M
Total debt
58.66M
Return on equity
61.42%
Short % of float
5.88%

Fundamental scorecard

16 of 25 checks passed on AUPH’s reported financials

ValueGrowthProfitabilityHealthDividend

16of 25 checks passed

  • Value 4 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AUPH Revenue — quarterly 83.70M
AUPH Net income — quarterly 31.70M
AUPH EPS — quarterly 0.24

Earnings

AUPH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20260.24———
Oct 30, 2026Sep 30, 20260.220.23+0.01+4.55%
Aug 6, 2026Jun 30, 20260.240.28+0.04+16.67%
May 7, 2026Mar 31, 20260.180.25+0.07+38.89%
Feb 26, 2026Dec 31, 20250.210.26+0.05+23.81%
Nov 4, 2025Sep 30, 20250.160.23+0.07+43.75%

Upgrades / downgrades

AUPH analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026RBC CapitalmainSector PerformSector Perform
Oct 21, 2026TD CowenmainBuyBuy
Aug 7, 2026RBC CapitalmainSector PerformSector Perform
Dec 3, 2025Leerink PartnersdownOutperformMarket Perform
Nov 7, 2025JefferiesupHoldBuy
Nov 5, 2025RBC CapitaldownOutperformSector Perform

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada

News

Your note

Sign in to keep a note on AUPH — it syncs with the Stock Master app.

Insider holders

AUPH insider holders
InsiderRelationLatest transactionDateShares held
BAILEY JEFFREY ALLENDirectorStock Award(Grant)Nov 20, 202425,491
COLE RYANChief Operating OfficerStock Award(Grant)May 17, 2026116,144
DONLEY MATTHEW MAXWELLChief Operating OfficerStock Award(Grant)Feb 26, 2026680,299
GREENLEAF PETER SChief Executive OfficerStock Award(Grant)Feb 26, 20261,840,380
HEARNE MICHAEL S.Chief Financial OfficerStock Award(Grant)May 17, 2026116,144
JAYNE DAVID ROLAND WALKERDirectorStock Award(Grant)Nov 20, 202456,499

Institution ownership

AUPH institution ownership
Holder% heldSharesValueReported
Tang Capital Management, LLC9.73%13,044,106194.23MSep 29, 2026
Blackrock Inc.6.41%8,585,378127.84MSep 29, 2026
Goldman Sachs Group Inc4.73%6,338,86694.39MSep 29, 2026
NEA Management Company, LLC2.96%3,969,83459.11MSep 29, 2026
Arrowstreet Capital, Limited Partnership2.23%2,984,79744.44MSep 29, 2026
Two Sigma Investments, LP2.20%2,953,59043.98MSep 29, 2026

Fund ownership

AUPH fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Russell 2000 ETF2.31%3,089,77046.01MSep 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.97%1,305,25719.44MAug 30, 2026
iShares Trust-iShares Russell 2000 Growth ETF0.83%1,116,70716.63MSep 29, 2026
iShares Trust-iShares Biotechnology ETF0.68%917,68313.66MSep 29, 2026
VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund0.51%683,82410.18MAug 30, 2026
Goldman Sachs Trust-Goldman Sachs U.S. Tax-Managed Equity Fund0.40%541,4438.06MJun 29, 2026